In this paper, we aimed to analyze the data collected in the last 15 years from patients with homozygous or heterozygous FH treated with LA in order to elucidate the benefit of this procedure with respect to plasma lipids, selected biomarkers of inflammation, endothelial dysfunction, and soluble endoglin. The gene discussed is ENG; the disease is familial hyperaldosteronism.